The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model

Drug Metabolism and Disposition

Volumn 33, Issue 1, 2005, Pages 165-174

  Doran, Angela ^a   Obach, R Scott ^a   Smith, Bill J ^a   Hosea, Natilie A ^a   Becker, Stacey ^a   Callegari, Ernesto ^a   Chen, Cuiping ^a   Chen, Xi ^a   Choo, Edna ^a   Cianfrogna, Julie ^a   Cox, Loretta M ^a   Gibbs, John P ^a   Gibbs, Megan A ^a   Hatch, Heather ^a   Hop, Cornelis E C A ^a   Kasman, Ilana N ^a   LaPerle, Jennifer ^a   Liu, JianHua ^a   Liu, Xingrong ^a   Logman, Michael ^a   Maclin, Debra ^a   Nedza, Frank M ^a   Nelson, Frederick ^a   Olson, Emily ^a   Rahematpura, Sandhya ^a   Raunig, David ^a   Rogers, Sabrinia ^a   Schmidt, Kari ^a   Spracklin, Douglas K ^a   Szewc, Mark ^a   Troutman, Matthew ^a   Tseng, Elaine ^a   Tu, Meihua ^a   Van Deusen, Jeffrey W ^a   Venkatakrishnan, Karthik ^a   Walens, Gary ^a   Wang, Ellen Q ^a   Wong, Diane ^a   Yasgar, Adam S ^a   Zhang, Chenghong ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; CARISOPRODOL; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CYCLOBENZAPRINE; DIAZEPAM; DRUG METABOLITE; ETHOSUXIMIDE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; HALOPERIDOL; HYDROCODONE; HYDROXYZINE; LAMOTRIGINE; MEPROBAMATE; METHYLPHENIDATE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; NORTRIPTYLINE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; DRUG UTILIZATION; EVALUATION; FEMALE; HEMOCONCENTRATION; KNOCKOUT MOUSE; MEASUREMENT; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT INDICATION; WILD TYPE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS;

ANIMALIA;

EID: 19944425121     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001230     Document Type: Article

References (31)

1. Aquilante CL, Letrent SP, Pollack GM, and Brouwer KLR (1999) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:PL47-PL51.
2. 123I]epidepride SPET study. J Clin Psychopharm 23:5-14.
3. Chen C, Hanson E, Watson JW, and Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31:312-318.
4. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
5. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
6. Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
7. Drewe J, Ball HA, Beglinger C, Peng B, Kemmler A, Schachinger H, and Haefeli WE (2000) Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 50:237-246.
8. Goadsby PJ (2000) The pharmacology of headache. Prog Neurobiol 62:509-525.
9. Gralla RJ (1983) Metoclopramide. A review of antiemetic trials. Drugs 25 (Suppl 1):63-73.
10. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, Van Der Graaf WTA, Willemsen ATM, Vaalburg W, and Franssen EJF (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
11. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, and Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134.
12. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CEAC, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, et al. (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581-587.
13. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BPR, and Van Royen E (1999) Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res 92:33-44.
14. Letrent SP, Pollack GM, Brouwer KR, and Brouwer KLR (1999) Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptic effect of morphine in the rat. Drug Metab Dispos 27:827-834.
15. Maurer TS, DeBartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
16. Mealey KL, Northrup NC, and Bentjen SA (2003) Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDRI deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 223:1453-1455.
17. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabijt-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
18. Roulet A, Fuel O, Gesta S, Lepage JF, Drag M, Soll M, Alvinerie M, and Pineau T (2003) MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 460:85-91.
19. Schinkel AH, Wagenaar E, Mol CAAM, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
20. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage KS, DeLoore K, and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
21. Singamma M and Prabhakara Rao P (1992) Anticholinesterase activity of metoclopramide. Curr Med Prac 36:296-303.
22. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, and Lotsch J (2003) Respiratory and mitotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74:303-311.
23. Thummel KE and Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed (Hardman JG and Limbird LE eds) pp 1917-2023, McGraw-Hill, New York.
24. Tolle-Sander S, Rautio J, Wring SA, Polli JW, and Polli JE (2003) Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res (NY) 20:757-764.
25. Troutman MD, Luo G, Gan LS, and Thakker DR (2002) The role of P-glycoprotein in drug disposition: significance to drug development, in Drug-Drug Interactions (Rodrigues AD ed) pp 295-357, Marcel Dekker, New York.
26. Uhr M and Grauer MT (2003) abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psych Res 37:179-185.
27. Uhr M, Grauer MT, and Holsboer F (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840-846.
28. Uhr M, Steckler T, Yassourdis A, and Holsboer F (2000) Penetration of amitriptyline, but not fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387.
29. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, and Beare CM (1997) Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88-94.
30. Yamazaki M, Neway WE, Ohe T, Chen IW, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
31. Zong J and Pollack GM (2000) Morphine antinociception is enhanced in mdr1a gene deficient mice. Pharm Res (NY) 17:749-763.